Business Wire

Telefónica Deutschland Selects Mavenir vIMS for Deployment on ‘UNICA’

Jaa

Mavenir, the leader in accelerating and redefining mobile network economics transformation for Communications Service Providers (CSPs), today announced that Telefónica Deutschland (FWB: O2D) is deploying Mavenir’s virtualized IMS solution (vIMS) for VoLTE and VoWiFi in their nationwide UNICA Data Centers Infrastructure, which is based on the Telefónica Group blueprint for Network Functions Virtualization (NFV) architecture.

The solution will support mobile and fixed services for more than 45 million customer connections. The NFV environment is based on OpenStack® and will include automation, life cycle management and integration with Management and Orchestration (MANO) capabilities from the Telefónica UNICA platform. The Mavenir advanced vIMS solution will enable automation from day one and will support existing voice digital services as well as the launch of new services.

As a software-based company leading the Telco NFV industry, Mavenir is a perfect match with Telefónica UNICA NFV strategy, where the company can offer very flexible and optimized solutions to Telefónica, reducing the Total Cost of Ownership (TCO) and opening countless possibilities of new services. Mavenir vIMS will allow Telefónica Deutschland to offer new propositions for all customer segments, moving the Telco services to the new era of IP convergence and Virtualisation.

“Telefónica’s UNICA NFV initiative will leverage the benefits of cloud-native software applications and enhanced automation to evolve towards future Next Generation architecture,” said Cayetano Carbajo, Chief Technology Officer at Telefónica Deutschland. “It is an important step in our transformation of the core infrastructure, and we are looking forward to going through this journey with Mavenir, a partner chosen for their advanced technology and innovation in NFV.”

“Mavenir is totally committed to providing excellent performances and operations based on the company's extensive and unique experience in IMS solutions,” said Pardeep Kohli, President and CEO of Mavenir. “We will continue to provide greater flexibility, greater efficiencies, and more agility in terms of innovation as a full end-to-end 4G LTE and 5G, IoT network provider.”

About Telefónica Deutschland:

Telefónica Deutschland offers telecommunications services for private and business customers, as well as innovative digital products and services in the fields of the Internet of Things and data analytics. With a total of 49.4 million customer connections (as of 30 June 2018), the company is one of the leading integrated telecommunications providers in Germany. In the mobile segment alone, Telefónica Deutschland is responsible for more than 45.2 million connections – no other domestic network operator connects more people. By 2022, the company aims to become the “Mobile Customer & Digital Champion”, meaning the preferred partner for customers in the German mobile service market that allows them mobile freedom in the digital world. Through its core brand O2 and various secondary and partner brands, the company sells postpaid and prepaid mobile telecommunications products including innovative mobile data services. The basis for this is a mobile service network based on a high-performance GSM, UMTS and LTE infrastructure. Telefónica Deutschland also provides telephony and high-speed internet products, such as VDSL, in the fixed network field. Telefónica Deutschland Holding AG has been listed in the Prime Standard on the Frankfurt Stock Exchange (TecDAX) since 2012. In the 2017 financial year, the company generated revenue of EUR 7.3 billion with almost 9,300 employees. The company is majority owned by the Spanish telecommunications group Telefónica S.A., headquartered in Madrid. With a presence in 21 countries and a customer base of almost 350 million connections, the group is one of the world’s biggest telecommunications providers.

1) Access numbers on a market-comparable basis. Status: 30 June 2018

About Mavenir:

Mavenir is purpose-built to redefine mobile network economics for Communication Service Providers (CSPs). Our innovative solutions pave the way to 5G with 100% software-based, end-to-end, Cloud Native network solutions. Leveraging industry-leading firsts in VoLTE, VoWiFi, Advanced Messaging (RCS), Multi-ID, vEPC and Cloud RAN, Mavenir accelerates network transformation for more than 250+ CSP customers in over 130 countries, serving over 50% of the world’s subscribers.

We embrace disruptive, innovative technology architectures and business models that drive service agility, flexibility, and velocity. With solutions that propel NFV evolution to achieve web-scale economics, Mavenir offers solutions to help CSPs with cost reduction, revenue generation and revenue protection. Learn more at mavenir.com.

Mavenir, the M logo, and Cloud Range are trademarks owned by Mavenir Systems, Inc.

Copyright © 2018 Mavenir Systems, Inc. All Rights Reserved.

Contact information

Mavenir
Maryvonne Tubb
PR@mavenir.com
or
MatterNow
Lydia Fakhouri
mavenir@matternow.com
or
GlobalResultsPR
Kevin Taylor
mavenir@globalresultspr.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

European Commission approves Ipsen’s Cabometyx® (cabozantinib) for the treatment of hepatocellular carcinoma in adults previously treated with sorafenib15.11.2018 09:30Tiedote

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the European Commission (EC) has approved Cabometyx® (cabozantinib) 20, 40, 60 mg as a monotherapy for hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib. This approval allows for the marketing of Cabometyx® (cabozantinib) in this indication in all 28 member states of the European Union, Norway and Iceland. “Today’s EC approval for the use of Cabometyx ® provides a much needed new option for HCC patients. Until now, physicians in Europe had only one approved therapy for the 2 nd line treatment of this aggressive and difficult-to-treat cancer.1,2 We are proud to offer Cabometyx ® as an innovative treatment that has been shown to extend survival in previously treated patients with HCC,” said Harout Semerjian, Chief Commercial Officer, Ipsen. “This new indication reinforces Ipsen’s commitment to improve patients’ lives through the expansion of the clinical benefit of Cabometyx ® i

Mobidiag nostaa viimeisen €4M erän Euroopan investointipankin €15M rahoituksesta15.11.2018 09:30Tiedote

Mobidiag Oy, vahvassa kasvuvaiheessa oleva molekyylidiagnostiikkayhtiö, joka taistelee antibioottiresistenssin leviämistä vastaan, ilmoitti tänään, että se on nostanut viimeisen 4 miljoonan euron erän 15 miljoonan euron lainasta, jonka Euroopan investointipankki (EIP) myönsi yhtiölle kolmivuotiseen projektiin heinäkuussa 2016. Laina myönnettiin osana EIP:n ”InnovFin - EU Finance for innovators” -ohjelmaa. Ohjelman tavoitteena on tukea innovatiivisten eurooppalaisten yhtiöiden haastavia korkean teknologian kehityshankkeita mahdollistamalla rahoituksen. Tämä lehdistötiedote sisältää multimediaa. Katso koko julkaisu täällä: https://www.businesswire.com/news/home/20181114005789/fi/ Aiemmin nostettujen EIP:n lainaerien avulla Mobidiag on kehittänyt valmiiksi ja kaupallistanut Novodiag® -molekyylidiagnostiikan järjestelmänsä sekä kaksi suolistoinfektioiden aiheuttajien tunnistamiseen käytettävää testiä (Novodiag® C. difficile ja Novodiag® Bacterial GE+). Viimeisen lainaerän avulla yhtiö nope

Mobidiag Receives Final €4M Tranche of €15M EIB Financing15.11.2018 09:30Tiedote

Mobidiag Ltd., a commercial stage molecular diagnostics company addressing the spread of antimicrobial resistance, announced today that it has received the final €4M tranche of a €15M three-year project secured by the Company from the European Investment Bank Group (EIB) in July 2016. The loan was provided as part of “InnovFin – EU Finance for innovators” programme, an EIB initiative aimed at providing innovative and high quality companies in Europe with access to finance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181114005786/en/ The EIB funding has already enabled Mobidiag to finalize, launch and commercialize its Novodiag® molecular diagnostic system and two assays for detection of gastrointestinal infections (Novodiag® C. difficile and Novodiag® Bacterial GE+). The final tranche will enable the Company to continue growing its product portfolio, accelerate the development of further assays for the Novodiag® system an

Highlights of China’s No. 1 High-Tech Fair CHTF 201815.11.2018 05:00Tiedote

The 20th China Hi-Tech Fair (CHTF 2018) is being held from November 14-18 at the Shenzhen Convention and Exhibition Center with the theme “New Development Concept for High Quality Growth.” This year’s CHTF consists of exhibitions, forums, professional meetings, supporting activities, talents exchange meetings and overseas fairs, and features advanced manufacturing, next-generation information technology, AI, life sciences, new materials, new energy, as well as integration of real economy and future industries. Here are some of the highlights of CHTF 2018: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181114005654/en/ International and Belt & Road Pavilion of CHTF (Photo: Business Wire) Themed areas focusing on industry hotspots The IT exhibition will present themed areas like AI, smart manufacturing, smart automotive, sports technology, big data, cloud computing, IoT and blockchain; the environmental exhibition will highlig

MapleStory Prepares for Epic Battle Against the Black Mage in Gathering of Heroes Event15.11.2018 00:00Tiedote

MapleStory, the iconic global MMORPG from Nexon America, is bringing the first phase of its long-awaited battle with the sinister villain, the Black Mage. Between November 14 through November 28, players can take part in the “Gathering of Heroes” event to join the Maple Alliance and prepare their armies to soon combat the Black Mage. The Black Mage has long been the main antagonist behind MapleStory. His story originated with the role of bringing balance to Maple World, but turned dark as he realized the only way to save Maple World was to destroy it. Now that his seal has been broken, players will need to work together to defeat the legendary boss. The Gathering of Heroes event adds the Maple Alliance outpost, where players can hone their skills and prepare to level up in preparation of for their battle against the Black Mage, as well as adds various leveling updates. The main goal of the Alliance is to gather “Determination” and power up the holy light in the outpost to be able to fi

SpinalCyte Announces Sustained 12-Month MRI Outcomes After CybroCell™ Injection14.11.2018 23:07Tiedote

SpinalCyte, LLC, a Texas-based regenerative medicine company focused on regrowth of the spinal disc nucleus using its universal donor product, CybroCell™, today announced that a single injection of modified human dermal fibroblasts (HDFs), resulted in significant improvements of disc height and pain reduction 12 months after injection of the cell therapy for patients with degenerative disc disease (DDD). The trial assessed patients using the Oswestry Disability Index (ODI), Visual Analogue Scale (VAS) and disc height via MRI scans. Using composite scoring, 54% of the treatment arm patients met all three endpoints as compared to only 17% with the placebo (p=0.0003). Over 84% of patients in the treatment group of CybroCell™ or CybroCell™ with platelet rich plasma (PRP) injections had an increase or no change in disc height compared to 25% for the placebo saline injection. Analyzed individually, 83% of spinal discs that were injected with CybroCell™ had an increase or no change in disc he

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme